Jedd D Wolchok

List of Publications by Citations

230 papers	79,493 citations	101 h-index	251 g-index
251 ext. papers	98,842 ext. citations	18.1 avg, IF	8.17 L-index

#	Paper	IF	Citations
230	Improved survival with ipilimumab in patients with metastatic melanoma. *New England Journal of Medicine*, **2010**, 363, 711-23	59.2	10591
229	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *New England Journal of Medicine*, **2015**, 373, 23-34	59.2	5047
228	Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science*, **2015**, 348, 124-8	33.3	5003
227	Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *New England Journal of Medicine*, **2011**, 364, 2517-26	59.2	3396
226	Genetic basis for clinical response to CTLA-4 blockade in melanoma. *New England Journal of Medicine*, **2014**, 371, 2189-2199	59.2	2802
225	Cancer immunotherapy using checkpoint blockade. *Science*, **2018**, 359, 1350-1355	33.3	2480
224	Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clinical Cancer Research*, **2009**, 15, 7412-20	12.9	2380
223	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *New England Journal of Medicine*, **2017**, 377, 1345-1356	59.2	2030
222	Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *New England Journal of Medicine*, **2015**, 372, 2006-17	59.2	2001
221	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. *Science*, **2016**, 351, 1463-9	33.3	1758
220	Immune Checkpoint Blockade in Cancer Therapy. *Journal of Clinical Oncology*, **2015**, 33, 1974-82	2.2	1690
219	Immunologic correlates of the abscopal effect in a patient with melanoma. *New England Journal of Medicine*, **2012**, 366, 925-31	59.2	1503
218	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nature Genetics*, **2019**, 51, 202-206	36.3	1435
217	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. *Journal of Clinical Oncology*, **2015**, 33, 1889-94	2.2	1425
216	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. *Science Translational Medicine*, **2016**, 8, 328rv4	17.5	1281
215	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *New England Journal of Medicine*, **2019**, 381, 1535-1546	59.2	1260
214	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. *Lancet Oncology, The*, **2017**, 18, e143-e152	21.7	1010

213	Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. *Journal of Experimental Medicine*, **2013**, 210, 1695-710	16.6	948
212	Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. *Lancet Oncology, The*, **2010**, 11, 155-64	21.7	910
211	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. *Cell*, **2015**, 162, 974-86	56.2	872
210	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. *New England Journal of Medicine*, **2018**, 378, 1976-1986	59.2	865
209	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. *Nature*, **2017**, 545, 60-65	50.4	850
208	Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. *Journal of Clinical Oncology*, **2015**, 33, 3193-8	2.2	697
207	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. *Journal of Clinical Oncology*, **2017**, 35, 785-792	2.2	696
206	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. *Lancet Oncology, The* , **2018**, 19, 1480-1492	21.7	680
205	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. *JAMA - Journal of the American Medical Association*, **2016**, 315, 1600-9	27.4	666
204	Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. *Cancer Discovery*, **2018**, 8, 822-835	24.4	648
203	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. *Nature Reviews Clinical Oncology*, **2016**, 13, 273-90	19.4	640
202	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *New England Journal of Medicine*, **2015**, 373, 1270-1	59.2	631
201	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. *Lancet Oncology, The*, **2016**, 17, 1558-1568	21.7	627
200	KIT as a therapeutic target in metastatic melanoma. *JAMA - Journal of the American Medical Association*, **2011**, 305, 2327-34	27.4	619
199	RECIST 1.1-Update and clarification: From the RECIST committee. *European Journal of Cancer*, **2016**, 62, 132-7	7.5	607
198	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. *Nature*, **2017**, 551, 512-516	50.4	533
197	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. *Cancer Cell*, **2018**, 33, 843-852.e4	24.3	525
196	Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. *Nature Communications*, **2016**, 7, 10391	17.4	524

195	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. *Journal of Clinical Oncology*, **2016**, 34, 1510-7	2.2	509
194	Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. *Science Translational Medicine*, **2014**, 6, 226ra32	17.5	484
193	Overcoming resistance to checkpoint blockade therapy by targeting PI3K in myeloid cells. *Nature*, **2016**, 539, 443-447	50.4	475
192	Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. *Journal of Experimental Medicine*, **2013**, 210, 1389-402	16.6	452
191	Chromatin states define tumour-specific T cell dysfunction and reprogramming. *Nature*, **2017**, 545, 452-456	50.4	413
190	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. *Journal of Clinical Oncology*, **2016**, 34, 4102-4109	2.2	400
189	Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. *Cancer Cell*, **2012**, 22, 668-82	24.3	377
188	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. *Clinical Cancer Research*, **2016**, 22, 5487-5496	12.9	373
187	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. *Clinical Cancer Research*, **2016**, 22, 2908-18	12.9	372
186	Immune modulation in cancer with antibodies. *Annual Review of Medicine*, **2014**, 65, 185-202	17.4	366
185	Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. *Clinical Cancer Research*, **2010**, 16, 2861-71	12.9	347
184	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. *Nature*, **2017**, 551, 517-520	50.4	336
183	Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. *Journal of Clinical Oncology*, **2015**, 33, 1191-6	2.2	334
182	Determinants of COVID-19 disease severity in patients with cancer. *Nature Medicine*, **2020**, 26, 1218-1223	30.5	329
181	The many faces of the anti-COVID immune response. *Journal of Experimental Medicine*, **2020**, 217,	16.6	314
180	Targeting T Cell Co-receptors for Cancer Therapy. *Immunity*, **2016**, 44, 1069-78	32.3	314
179	The abscopal effect associated with a systemic anti-melanoma immune response. *International Journal of Radiation Oncology Biology Physics*, **2013**, 85, 293-5	4	304
178	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. *Journal of Clinical Oncology*, **2017**, 35, 226-235	2.2	302

177	Classification of current anticancer immunotherapies. *Oncotarget*, **2014**, 5, 12472-508	3.3	301
176	Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. *JAMA - Journal of the American Medical Association*, **2014**, 311, 2397-405	27.4	285
175	Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. *Cell Reports*, **2015**, 13, 412-24	10.6	275
174	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. *Journal of Clinical Oncology*, **2018**, 36, 1685-1694	2.2	274
173	Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. *International Journal of Radiation Oncology Biology Physics*, **2015**, 92, 368-75	4	268
172	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. *Cell*, **2017**, 170, 927-938.e20	56.2	267
171	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. *Journal of Clinical Oncology*, **2017**, 35, 3807-3814	2.2	264
170	Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. *Cancer Research*, **2012**, 72, 876-86	10.1	264
169	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. *Cancer Cell*, **2018**, 33, 581-598	24.3	261
168	The hallmarks of successful anticancer immunotherapy. *Science Translational Medicine*, **2018**, 10,	17.5	260
167	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. *JAMA Oncology*, **2019**, 5, 471-478	13.4	257
166	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. *Science Translational Medicine*, **2018**, 10,	17.5	227
165	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. *JAMA Oncology*, **2019**, 5, 1411-1420	13.4	216
164	Coupling and uncoupling of tumor immunity and autoimmunity. *Journal of Experimental Medicine*, **1999**, 190, 1717-22	16.6	214
163	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. *Cancer Immunology Research*, **2016**, 4, 383-9	12.5	199
162	The future of cancer immunotherapy: microenvironment-targeting combinations. *Cell Research*, **2020**, 30, 507-519	24.7	194
161	Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. *PLoS ONE*, **2010**, 5, e10436	3.7	194
160	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. *Journal of Clinical Oncology*, **2018**, 36, 850-858	2.2	184

159	Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. *Clinical Cancer Research*, **2016**, 22, 1364-70	12.9	182
158	Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. *Cancer Research*, **2006**, 66, 4904-12	10.1	179
157	The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. *Oncologist*, **2008**, 13 Suppl 4, 2-9	5.7	178
156	OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. *Journal of Experimental Medicine*, **2009**, 206, 1103-16	16.6	174
155	The efficacy of anti-PD-1 agents in acral and mucosal melanoma. *Cancer*, **2016**, 122, 3354-3362	6.4	164
154	Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. *JAMA Oncology*, **2015**, 1, 433-40	13.4	160
153	Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. *Journal of Clinical Oncology*, **2017**, 35, 3815-3822	2.2	160
152	Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. *Cancer Discovery*, **2020**, 10, 1121-1128	24.4	156
151	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. *Cancer Treatment Reviews*, **2014**, 40, 1056-64	14.4	146
150	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. *Clinical Cancer Research*, **2018**, 24, 4960-4967	12.9	142
149	Ipilimumab in patients with cancer and the management of dermatologic adverse events. *Journal of the American Academy of Dermatology*, **2014**, 71, 161-9	4.5	142
148	Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. *Cancer Discovery*, **2018**, 8, 1006-1025	24.4	141
147	Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. *Cell*, **2019**, 178, 933-948.e14	56.2	141
146	CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. *Nature Immunology*, **2020**, 21, 298-308	19.1	138
145	CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. *Frontiers in Oncology*, **2014**, 4, 385	5.3	135
144	Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma **2015**, 3, 23		134
143	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1CD38 cells and anti-PD-1 resistance. *Nature Immunology*, **2019**, 20, 1231-1243	19.1	132
142	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. *Cell Research*, **2015**, 25, 208-24	24.7	126

141	Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. *Journal of Clinical Oncology*, **2018**, 36, 391-398	2.2	118
140	RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. *European Journal of Cancer*, **2016**, 62, 138-45	7.5	117
139	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. *Oncologist*, **2016**, 21, 848-54	5.7	115
138	GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. *Cancer Immunology Research*, **2013**, 1, 320-31	12.5	114
137	On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. *Science Translational Medicine*, **2015**, 7, 280sr1	17.5	113
136	The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment. *Science Advances*, **2015**, 1, e1500845	14.3	113
135	Modulation of GITR for cancer immunotherapy. *Current Opinion in Immunology*, **2012**, 24, 217-24	7.8	112
134	Immunotherapy of Melanoma: Facts and Hopes. *Clinical Cancer Research*, **2019**, 25, 5191-5201	12.9	110
133	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. *Clinical Cancer Research*, **2016**, 22, 4848-4858	12.9	108
132	Future cancer research priorities in the USA: a Lancet Oncology Commission. *Lancet Oncology, The*, **2017**, 18, e653-e706	21.7	106
131	Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. *Investigational New Drugs*, **2013**, 31, 425-34	4.3	105
130	CD8 T cells contribute to survival in patients with COVID-19 and hematologic cancer. *Nature Medicine*, **2021**, 27, 1280-1289	50.5	103
129	Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. *JAMA Oncology*, **2018**, 4, 98-101	13.4	98
128	Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. *Cancer Immunology Research*, **2014**, 2, 812-21	12.5	97
127	Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. *Journal of Experimental Medicine*, **2012**, 209, 2113-26	16.6	97
126	Rational design of anti-GITR-based combination immunotherapy. *Nature Medicine*, **2019**, 25, 759-766	50.5	95
125	PD-1 Blockers. *Cell*, **2015**, 162, 937	56.2	95
124	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. *Cancer Immunology Research*, **2016**, 4, 835-844	12.5	95

123	Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. *Clinical Cancer Research*, **2015**, 21, 2289-96	12.9	90
122	Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. *EBioMedicine*, **2016**, 6, 50-58	8.8	86
121	First-in-Humans Imaging with Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. *Journal of Nuclear Medicine*, **2020**, 61, 512-519	8.9	86
120	Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy **2014**, 2, 7		85
119	Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. *Journal of Experimental Medicine*, **2009**, 206, 849-66	16.6	85
118	Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. *Cancer Immunology Research*, **2018**, 6, 189-200	12.5	84
117	Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. *Molecular Therapy*, **2007**, 15, 2044-50	11.7	82
116	Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. *Cancer Immunology Research*, **2016**, 4, 936-947	12.5	82
115	Non-conventional Inhibitory CD4Foxp3PD-1 T Cells as a Biomarker of Immune Checkpoint Blockade Activity. *Cancer Cell*, **2018**, 33, 1017-1032.e7	24.3	81
114	Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. *Nature Communications*, **2017**, 8, 14340	17.4	80
113	Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. *Cancer Immunology Research*, **2014**, 2, 70-9	12.5	80
112	PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. *Journal of Clinical Investigation*, **2018**, 128, 1413-1428	15.9	79
111	Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment **2017**, 5, 76		78
110	F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. *Journal of Nuclear Medicine*, **2019**, 60, 335-341	8.9	78
109	Cancer: Antitumour immunity gets a boost. *Nature*, **2014**, 515, 496-8	50.4	77
108	Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. *Cancer Immunology Research*, **2013**, 1, 235-44	12.5	75
107	Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. *Cancer Cell*, **2020**, 38, 500-515.e3	24.3	75
106	Combinatorial Cancer Immunotherapies. *Advances in Immunology*, **2016**, 130, 251-77	5.6	75

105	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. *Cell*, **2018**, 173, 624-633.e8	56.2	71
104	Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. *Cancer Immunology Research*, **2017**, 5, 84-91	12.5	70
103	Ipilimumab in patients with melanoma and autoimmune disease **2014**, 2, 35		70
102	Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. *Science Signaling*, **2017**, 10,	8.8	69
101	Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. *EBioMedicine*, **2017**, 18, 56-61	8.8	67
100	Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. *Science Immunology*, **2017**, 2,	28	66
99	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. *Nature Medicine*, **2020**, 26, 1114-1124	50.5	63
98	Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6cCD103 Monocytic Antigen-Presenting Cells in Tumors. *Immunity*, **2018**, 48, 91-106.e6	32.3	63
97	Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. *Molecular Therapy*, **2018**, 26, 1008-1019	11.7	62
96	Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. *Nature Communications*, **2020**, 11, 4011	17.4	60
95	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. *European Journal of Cancer*, **2017**, 73, 61-70	7.5	59
94	Immune checkpoint blockade. *Hematology/Oncology Clinics of North America*, **2014**, 28, 585-600	3.1	57
93	Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation. *Nature Communications*, **2015**, 6, 6840	17.4	56
92	Health-related quality of life results from the phase III CheckMate 067 study. *European Journal of Cancer*, **2017**, 82, 80-91	7.5	55
91	CTLA-4 blockade drives loss of T stability in glycolysis-low tumours. *Nature*, **2021**, 591, 652-658	50.4	52
90	The importance of animal models in tumor immunity and immunotherapy. *Current Opinion in Genetics and Development*, **2014**, 24, 46-51	4.9	49
89	Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. *New England Journal of Medicine*, **2015**, 372, 2073-4	59.2	47
88	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials **2016**, 4, 15		47

87	Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8 T cells in tumors. *Immunity*, **2021**, 54, 1561-1577.e7	32.3	47
86	Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. *PLoS ONE*, **2010**, 5, e12670	3.7	46
85	Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors. *Clinical Infectious Diseases*, **2020**, 70, 193-199	11.6	44
84	Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications. *Modern Pathology*, **2017**, 30, 599-609	9.8	43
83	Selective inhibition of low-affinity memory CD8 T cells by corticosteroids. *Journal of Experimental Medicine*, **2019**, 216, 2701-2713	16.6	43
82	Prognostic value of baseline metabolic tumor volume measured on F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 930-939	8.8	43
81	Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. *Nature Reviews Clinical Oncology*, **2021**,	19.4	42
80	Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	41
79	DNA vaccines: an active immunization strategy for prostate cancer. *Seminars in Oncology*, **2003**, 30, 659-66	3.5	41
78	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. *Journal of Clinical Oncology*, **2021**, JCO2102229	2.2	39
77	Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. *OncoImmunology*, **2016**, 5, e1151595	7.2	39
76	Putting the Immunologic Brakes on Cancer. *Cell*, **2018**, 175, 1452-1454	56.2	39
75	Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. *European Journal of Cancer*, **2016**, 64, 116-26	7.5	36
74	Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. *Melanoma Research*, **2003**, 13, 189-96	3.3	35
73	The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy. *Advances in Cancer Research*, **2015**, 128, 1-68	5.9	34
72	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. *Cancer Discovery*, **2021**, 11, 1212-1227	24.4	29
71	CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.. *Journal of Clinical Oncology*, **2021**, 39, 9506-9506	2.2	29
70	Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. *Oncologist*, **2015**, 20, 648-52	5.7	28

69	Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. *Molecular Therapy - Oncolytics*, **2014**, 1, 14004	6.4	28
68	Shared cancer neoantigens: Making private matters public. *Journal of Experimental Medicine*, **2018**, 215, 5-7	16.6	27
67	Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates. *Cancer Immunology Research*, **2014**, 2, 448-58	12.5	27
66	Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma **2013**, 1, 20		27
65	First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors.. *Journal of Clinical Oncology*, **2016**, 34, 3017-3017	2.2	26
64	TNF in the era of immune checkpoint inhibitors: friend or foe?. *Nature Reviews Rheumatology*, **2021**, 17, 213-223	8.1	26
63	Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. *Cell Reports*, **2019**, 27, 806-819.e5	10.6	25
62	Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion. *Immunity*, **2016**, 44, 179-193	32.3	25
61	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. *Cell*, **2021**, 184, 4032-4047.e31	36.2	25
60	Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. *Molecular and Cellular Oncology*, **2016**, 3, e1048929	1.2	24
59	In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. *Journal of Clinical Investigation*, **2019**, 129, 3435-3447	15.9	24
58	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. *European Journal of Cancer*, **2021**, 144, 182-191	7.5	23
57	Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience. *Oncologist*, **2019**, 24, e196-e197	5.7	22
56	The delicate balance of melanoma immunotherapy. *Clinical and Translational Immunology*, **2013**, 2, e5	6.8	21
55	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. *Annals of Surgical Oncology*, **2020**, 27, 1180-1188	3.1	21
54	Safety of Infusing Ipilimumab Over 30 Minutes. *Journal of Clinical Oncology*, **2015**, 33, 3454-8	2.2	19
53	Acquired resistance to immunotherapy in MMR-D pancreatic cancer **2018**, 6, 127		19
52	Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists. *Seminars in Oncology*, **2015**, 42, 573-86	5.5	17

51	Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. *Nature Medicine*, **2021**, 27, 1646-1654	50.5	17
50	Strategies for Predicting Response to Checkpoint Inhibitors. *Current Hematologic Malignancy Reports*, **2018**, 13, 383-395	4.4	17
49	Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. *Oncotarget*, **2018**, 9, 28702-28716	3.3	14
48	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. *Science Translational Medicine*, **2021**, 13,	17.5	14
47	Tim-4 cavity-resident macrophages impair anti-tumor CD8 T cell immunity. *Cancer Cell*, **2021**, 39, 973-988.e9	24.3	13
46	Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. *European Journal of Cancer*, **2019**, 112, 29-31	7.5	12
45	Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope. *PLoS ONE*, **2011**, 6, e21214	3.7	12
44	Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma **2019**,		12
43	Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. *Melanoma Research*, **2020**, 30, 71-75	3.3	12
42	Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?. *Cancer Cell*, **2019**, 36, 215-217	24.3	11
41	Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading. *Ophthalmology*, **2020**, 127, 240-248	7.3	11
40	Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment. *Experimental Dermatology*, **2016**, 25, 553-4	4	11
39	CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer **2021**,		11
38	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. *Cancer Immunology Research*, **2021**, 9, 1202-1213	12.5	11
37	Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?. *Cancer Discovery*, **2016**, 6, 1210-1211	24.4	10
36	Enhanced responses to tumor immunization following total body irradiation are time-dependent. *PLoS ONE*, **2013**, 8, e82496	3.7	10
35	Patient perspectives on ipilimumab across the melanoma treatment trajectory. *Supportive Care in Cancer*, **2017**, 25, 2155-2167	3.9	7
34	Genetics and immunology: reinvigorated. *OncoImmunology*, **2015**, 4, e1029705	7.2	7

33	Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study **2021**, 9,		6
32	Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma. *Methods in Molecular Biology*, **2014**, 1102, 83-95	1.4	6
31	Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. *Cell Reports*, **2021**, 34, 108620	10.6	6
30	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. *Clinical Cancer Research*, **2021**, 27, 2226-2235	12.9	6
29	Abstract CT018: Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial **2017**,		5
28	Curbing TregsR(Lack of) Enthusiasm. *Cell*, **2017**, 169, 981-982	56.2	4
27	PD-L1 Blockade Therapy: Location, Location, Location. *Cancer Cell*, **2020**, 38, 615-617	24.3	3
26	Anatomic position determines oncogenic specificity in melanoma.. *Nature*, **2022**,	50.4	3
25	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.. *Nature Communications*, **2022**, 13, 1935	17.4	3
24	Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors. *American Journal of Ophthalmology Case Reports*, **2020**, 19, 100799	1.3	2
23	Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).. *Journal of Clinical Oncology*, **2021**, JCO2101570	2.2	2
22	Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 **2021**, 9,		2
21	Isoform specific anti-TGFtherapy enhances antitumor efficacy in mouse models of cancer. *Communications Biology*, **2021**, 4, 1296	6.7	2
20	Oxidized Lipids and CD36-Mediated Lipid Peroxidation in CD8 T Cells Suppress Anti-Tumor Immune Responses		2
19	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. *European Journal of Cancer*, **2021**, 157, 391-402	7.5	2
18	A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. *OncoImmunology*, **2021**, 10, 1898105	7.2	2
17	Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma. *Cancers*, **2022**, 14, 2638	6.6	2
16	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab **2021**, 9,		1

15	Characteristics and probability of survival for patients with advanced melanoma who live five or more years after initial treatment with immune checkpoint blockade (ICB).. *Journal of Clinical Oncology*, **2021**, 39, 9534-9534	2.2	1
14	Patient-Physician Communication in the 21st Century. *Trends in Immunology*, **2016**, 37, 347-349	14.4	1
13	Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia **2021**, 9,		1
12	Fundamental immune-oncogenicity trade-offs define driver mutation fitness.. *Nature*, **2022**,	50.4	1
11	Checkpoint blockade: the end of the beginning. *Nature Reviews Immunology*, **2021**, 21, 621	36.5	0
10	Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism.. *Science Advances*, **2022**, 8, eabm4552	14.3	0
9	Checkpoint Blockade **2018**, 37-53		
8	Refusing to TAP out: 16 new human TEIPPs identified. *Journal of Experimental Medicine*, **2018**, 215, 2233-2234	12.6	
7	Alan Houghton. *Pigment Cell and Melanoma Research*, **2012**, 25, 401	4.5	
6	DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mouse Models of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).. *Blood*, **2004**, 104, 304-304	2.2	
5	DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mice Following Sub-Lethal Irradiation and Immune Reconstitution.. *Blood*, **2004**, 104, 3057-3057	2.2	
4	Chromatin State Dynamics Underlying CD8 T Cell Differentiation and Dysfunction in Cancer. *Blood*, **2016**, 128, 861-861	2.2	
3	Reply to: Combining TNF blockade with immune checkpoint inhibitors in patients with cancer. *Nature Reviews Rheumatology*, **2021**, 17, 577-578	8.1	
2	Reply to A. Indini et al. *Journal of Clinical Oncology*, **2016**, 34, 1018-9	2.2	
1	Reply to T. Olivier et al.. *Journal of Clinical Oncology*, **2022**, JCO2200209	2.2	